诱导多能干细胞
重编程
药物发现
药物开发
再生医学
类有机物
疾病
干细胞
体细胞
神经科学
生物
医学
计算生物学
药品
生物信息学
细胞
药理学
胚胎干细胞
细胞生物学
病理
遗传学
基因
作者
Stevephen Hung,Shahnaz Khan,Camden Lo,Alex W. Hewitt,Raymond Ching-Bong Wong
标识
DOI:10.1016/j.pharmthera.2017.02.026
摘要
The revolution of induced pluripotent stem cell (iPSC) technology provides a platform for development of cell therapy, disease modeling and drug discovery. Recent technological advances now allow us to reprogram a patient’s somatic cells into induced pluripotent stem cells (iPSCs). Together with methods to differentiate these iPSCs into disease-relevant cell types, we are now able to model disease in vitro using iPSCs. Importantly, this represents a robust in vitro platform using patient-specific cells, providing opportunity for personalized precision medicine. Here we provide a review of advances using iPSC for drug development, and discuss the potential and limitations of iPSCs for drug discovery in neurodegenerative and ocular diseases. Emerging technologies that can facilitate the search for new drugs by assessment using in vitro disease models will also be discussed, including organoid differentiation, organ-on-chip, direct reprogramming and humanized animal models.
科研通智能强力驱动
Strongly Powered by AbleSci AI